Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607334 | 0.94 | LRRK2 (0.35) | LRRK2PIK3CAPDE4BNPC1RAB9A | |
| SCHEMBL4932463 | 0.90 | LRRK2 (0.40) | LRRK2PDE4B | |
| SCHEMBL4607307 | 0.88 | LRRK2 (0.33) | LRRK2PIK3CAPDE4BNPC1RAB9A | |
| SCHEMBL4607356 | 0.83 | MAPK14 (0.34) | LRRK2PIK3CANPC1RAB9A | |
| SCHEMBL4929148 | 0.81 | PIK3CA (0.32) | LRRK2PIK3CANPC1RAB9A | |
| SCHEMBL4607056 | 0.81 | PIK3CA (0.33) | LRRK2PIK3CANPC1RAB9A | |
| SCHEMBL4607631 | 0.79 | LRRK2 (0.44) | LRRK2 | |
| SCHEMBL4931333 | 0.79 | SLC2A1 (0.40) | LRRK2PIK3CANPC1RAB9ACNR2 | |
| SCHEMBL14034575 | 0.79 | LRRK2 (0.32) | LRRK2PIK3CANPC1RAB9A | |
| SCHEMBL4608343 | 0.77 | LRRK2 (0.50) | LRRK2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | claimed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | claimed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | LRRK2 2855/4885BRAF 4493/4885PIK3CA 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.